SlideShare a Scribd company logo
Pathophysiology of T2 Diabetes and its
Clinical implications.

INTESSAR SULTAN
单击此处编辑母版副标题样式
MD, MRCP
PROF. OF MEDICINE @ TAIBA UNIVERSITY.
CONSULTANT ENDOCRINOLOGIST@ DC, KFH,
MADINAH.
DEFINITION
Diabetes mellitus is metabolic disorder of
multiple aetiology characterized by chronic
hyperglycaemia with disturbances of
carbohydrate, fat and protein metabolism
resulting from defects in insulin secretion,
insulin action, or both.
.
NORMAL FUEL
METABOLISM
NORMAL FUEL METABOLISM
Fuel metabolism is regulated by complex system to:
• Distribute nutrients to organs and tissues for mechanical or
chemical work, growth or renewal
• Provide storage of excess nutrients: glycogen or fat
• Allow release of energy from storage depots as needed during
fasting or high energy use
Carbohydrate Metabolism
• Glucose is a major energy source for muscles
and the brain.
• The brain is nearly totally dependent on
glucose
• Muscles use Glucose And Fat for fuel.
• Main sources of circulating glucose are hepatic
glucose production, kidney and ingested
carbohydrate.
Basal Hepatic glucose production:
HGP
• After absorption of the last meal is
complete, liver produce glucose to supply
glucose needed for tissues that do not
store glucose as brain.
• ~2 mg/kg body wt/min in adults.
BRIAN
• Do not store glucose
• Dependent on glucose
Mechanisms and sources of glucose
release in the post-absorptive state
Renal contribution:
2.0–2.5
μmol/(kg−min)
(20–25%)

Hepatic contribution:
7.5–8.0
μmol/(kg−min)
(75–80%)

Hepatic
glycogenolysis:
4.5–5.5
μmol/(kg−min)
(45–50%)

Renal
gluconeogenesis:
2.0–2.5
μmol/(kg−min)
(20–25%)

Hepatic
gluconeogenesis:
2.5–3.0
μmol/(kg−min)
(25–30%)

Overall rate of glucose
release:
~10 μmol/(kg−min)
High HGP In T2DM
• Insulin suppresses hepatic glucose production (HGP)
• In T2D: impaired hepatic insulin action (Liver
resistance): increase BGP: high FBG: diagnosis
• High HGP during fasting : hyperglycemia,
hyperlipidemia, and ketosis (RAMADAN
FASTING).
• Metformin: act on liver resistance. Taken at PM ,
lowers liver production of glucose at night, lowers
FBG .
Ingested carbohydrate
• 60–70% is stored (glycogen)
• 30-40% oxidized for immediate energy needs.
• Produce postprandial blood glucose 90–120 min after meal.
• The magnitude and rate of rise in BG:
– size of the meal
– physical state (solid, liquid, cooked, raw)
– other nutrients: fat and fiber: slow digestion
– amount and effect of insulin.
– Type simple or complex: least effect
– The rate of gastric emptying: delays PP surge with
hypoglycemia and rebound hyperglycemia
Protein Metabolism
Ingested protein is absorbed as amino
acids:
• synthesis of new protein
• oxidation to provide energy
• conversion to glucose (gluconeogenesis)
during fasting: Alanine
• In DM: gluconeogenesis: loss of weight
and Fatigue
Fat Metabolism
• Fat is the major form of stored energy as triglyceride
in adipose tissue or muscle fat deposits.
• TG is converted to free fatty acids plus glycerol by
lipolysis: transported to muscle for oxidation: ketone
bodies acetoacetate and –hydroxybutyrate .
• Chronic nutritional excess: accumulation of stored
fat, because ingested fat is not used and other excess
nutrients (glucose) are used to synthesize fat: fatty
liver.
CLINICAL IMPLICATIONS
• Elevated circulating free fatty acids from
ingested fat or lipolysis may:
• induce hepatic insulin resistance at
different sites: LIPOTOXICITY
• Increase basal HGP
• Slow the postabsorptive decline in blood
glucose.
HORMONAL REGULATION
OF FUEL METABOLISM
Insulin and Glucose Metabolism
Major Metabolic Effects of
Insulin

• Stimulates glucose uptake into muscle and
adipose cells: lipogenesis
• Inhibits hepatic glucose production
Consequences of Insulin
Deficiency
• Hyperglycemia  osmotic diuresis and
dehydration
Major Metabolic Effects of Insulin and Consequences of
Insulin Deficiency
Insulin effects: Stimulates glucose uptake into muscle and
adipose cells: lipogenesis + inhibits lipolysis
Consequences of insulin deficiency: elevated FFA levels

Insulin effects: Inhibits ketogenesis
• Consequences of insulin deficiency: ketoacidosis,
production of ketone bodies

Stimulates glucose uptake into muscle

stimulates amino acid uptake and protein synthesis, inhibits
protein degradation, regulates gene transcription
• Consequences of insulin deficiency: muscle wasting
Insulin secretion
Pathophysiology of diabetes final 2
Basal Insulin
• Constant low insulin levels
• Prevent lipolysis and glucose production.
• Low level of basal Insulin during exercise
making stored energy available.
• Low basal insulin during fasting: increase
glucagon : glycogenolysis , lipolysis, and
ketogenesis: hyperglycemia, hyperlipidemia,
and ketosis.
Prandial insulin
• Blood glucose is the dominant stimulus for
insulin secretion.
• Postprandial secretion increases rapidly> basal
– Suppress glucose production
– Supress lipolysis
– stimulate uptake of ingested glucose by tissues
The Biphasic prandial Insulin Response

Adapted from Howell SL. Chapter 9. In: Pickup JC, Williams G (Eds). Textbook of Diabetes. Oxford.
Blackwell Scientific Publications 1991: 72–83.
Insulin Secretion

Fig. 47-1
Loss of Early-phase Insulin Release in Type 2 Diabetes

Pattern of insulin release is altered early in Type 2 diabetes

120
100

20g
glucose

80
60
40
20
0
–30 0 30 60 90 120
Time (minutes)

Type 2 diabetes
Plasma insulin (µU / ml)

Plasma insulin (µU/ml)

Normal
120

20g glucose

100
80
60
40

20
0
–30 0 30 60 90 120
Time (minutes)

Adapted from Ward WK et al. Diabetes Care 1984; 7: 491–502.
Overview of Insulin and Action
Insulin Preparations

Fig. 47-3
Glucotoxicity
• Hyperglycemia inhibits insulin secretion and
impairs insulin action.
• Oral agents that increase insulin secretion or
improve action could be ineffective at higher
levels of hyperglycemia.
• Treatment with insulin for a few days to
reduce the marked hyperglycemia may make
the patient more responsive to subsequent
treatment with oral agents.
Normal glucose homeostasis

Insulin-mediated glucose uptake by
skeletal muscle and adipose tissue

Glucagon
Insulin

FPG 90 mg/dL
Glucose

Glucose
filtration/
reabsorption

FPG, fasting plasma glucose.
Adapted from: DeFronzo RA. Ann Intern Med 1999;131:281–303; Wright EM. Am J Physiol Renal Physiol 2001;280:F10–F18.
Pathophysiology in Type 2 DM
1.Decreased insulin and increased glucagon
secretion result in...
2.elevated hepatic glucose output...
3. reduced insulin-mediated glucose uptake
4.Hyperglycaemia
5.Renal glucose filtration and reabsorption is
increased up to the renal threshold for glucose
reabsorption (180 mg/dL): glucosuria
6.Glucotoxicity of all organs, exposing the
individual to the risk of complications and further
impairing insulin secretion and action
Pathophysiology of Type 2
diabetes
Insulin-mediated glucose uptake by
skeletal muscle and adipose tissue

 Glucagon
1

 Insulin
FPG 90 mg/dL
Glucose

Glucose
filtration/
reabsorption

FPG, fasting plasma glucose.
Adapted from: DeFronzo RA. Ann Intern Med 1999;131:281–303; Wright EM. Am J Physiol Renal Physiol 2001;280:F10–F18.
Pathophysiology of Type 2 diabetes




Insulin resistance is the decreased
response of the liver and peripheral
tissues (muscle, fat) to insulin
Insulin resistance is a primary defect in the
majority of patients with Type 2 diabetes
Pathophysiology of Type 2
diabetes
Insulin-mediated glucose uptake by
skeletal muscle and adipose tissue

 Glucagon

 Insulin

1

FPG 90 mg/dL
2

 Glucose

Glucose
filtration/
reabsorption

FPG, fasting plasma glucose.
Adapted from: DeFronzo RA. Ann Intern Med 1999;131:281–303; Wright EM. Am J Physiol Renal Physiol 2001;280:F10–F18.
Pathophysiology of Type 2
diabetes
3
Insulin-mediated glucose uptake by

skeletal muscle and adipose tissue

 Glucagon

 Insulin

1

FPG 90 mg/dL
2

 Glucose

Glucose
filtration/
reabsorption

FPG, fasting plasma glucose.
Adapted from: DeFronzo RA. Ann Intern Med 1999;131:281–303; Wright EM. Am J Physiol Renal Physiol 2001;280:F10–F18.
Pathophysiology of Type 2
diabetes
3
Insulin-mediated glucose uptake by

skeletal muscle and adipose tissue

 Glucagon

 Insulin

1

FPG 90 mg/dL
2

 Glucose
4
 Glucose

filtration/
reabsorption

FPG, fasting plasma glucose.
Adapted from: DeFronzo RA. Ann Intern Med 1999;131:281–303; Wright EM. Am J Physiol Renal Physiol 2001;280:F10–F18.
Pathophysiology of Type 2 diabetes

3
Insulin-mediated glucose uptake by

skeletal muscle and adipose tissue

 Glucagon

 Insulin

1

FPG 180 mg/dL
2

GLUCOTOXICITY

 Glucose
4
 Glucose

filtration/
reabsorption

GLUCOSURIA

FPG, fasting plasma glucose.
Adapted from: DeFronzo RA. Ann Intern Med 1999;131:281–303; Wright EM. Am J Physiol Renal Physiol 2001;280:F10–F18.
Pathophysiology of Type 2 diabetes

3
Insulin-mediated glucose uptake by

skeletal muscle and adipose tissue

 Glucagon

 Insulin

1

FPG 180 mg/dL
2

GLUCOTOXICITY

 Glucose
4
 Glucose

filtration/
reabsorption

GLUCOSURIA

FPG, fasting plasma glucose.
Adapted from: DeFronzo RA. Ann Intern Med 1999;131:281–303; Wright EM. Am J Physiol Renal Physiol 2001;280:F10–F18.
Glucogen synthesis 

Glucose oxidation 
Glucogen catabolism 
Hepatic glucose production

Adipocytes uptake TG 
Lipid synthesis  (lipoproteinesterase activity )

Lipid mobilization (Hormone sensitive lipase )
ketone (acetone, acetoacetic acid,
beta-hydroxybutyric acid)
DeFronzo RA. Diabetes. 2009;58:773-795.
KIDNEY
An adaptive response to
conserve glucose....
Glucose

...becomes maladaptive
in Type 2 diabetes
GLUCOSE

SGLT2 plays a crucial role in
renal glucose reabsorption
In Type 2 diabetes, the
kidney’s maximum glucose
reabsorption threshold is
exceeded, resulting in
glycosuria
This highlights renal glucose
reabsorption as a potential target
for treatment of Type 2 diabetes
Normal urine

GLUCOSURIA
SGLT2, sodium-glucose co-transporter-2.
Pathophysiologic Approach
to Treatment of T2DM
Impaired Insulin Secretion


Metformin
Thiazolidinediones

_

TZDs
GLP-1 analogues
DPP-4 inhibitors
Sulfonylureas
Thiazolidinediones
Metformin



Hyperglycemia
Increased
Hepatic
Glucose
Production

Decreased
Glucose
Uptake

DeFronzo RA. Diabetes. 2009;58:773-795.
Mechanism of action-SU
repaglinide (36 kD)
Kir 6.2
nateglinide

SUR

depolarization

SUR

ATP
glimipiride(65 kD)
glyburide(140 kD)
Mechanism of action- acarbose
Reversible inhibition of oligosaccharide
breakdown by -glucosidases

Acarbose

Acarbose

Oligosaccharide

Small intestine
mucosa
SGLT-2 INHIBITORS
SGLTs
SGLT1

SGLT2

Site

Mostly intestine with some
in the kidney

Nearly exclusively in the
kidney

Sugar specificity

Glucose or galactose

Glucose

Affinity for glucose

High
Km = 0.4 mM

Low
Km = 2 mM

Capacity for glucose
transport

Low

High

Role

Dietary glucose absorption
Renal glucose reabsorption

Renal glucose reabsorption

SGLT1/2, sodium-glucose co-transporter-1/2.
Abdul-Ghani MA, et al. Endocr Pract 2008;14:782–90.
Counter regulatory hormones
Glucagon.
• The first line of defense against
hypoglycemia in normals
• Glucagon rises rapidly when blood
glucose levels fall and stimulates HGP.
• In type 1 diabetes, glucagon secretion in
response to hypoglycemia may be lost.
Catecholamines.
• Produced at times of stress (“fight or flight”)
• Stimulate release of stored energy.
• Major defense against hypoglycemia in T1M
(POOR glucagon).
• IF DEFECTIVE: Hypoglycemia unawareness:
severe and prolonged hypoglycemia:
• Intensified glucose control only after a period
of hypoglycemia avoidance and restoration of
catecholamine response.
Cortisol.
•
•
•
•

increases at times of stress.
stimulate gluconeogenesis.
slower than glucagon
not effective in protecting against
acute hypoglycemia.
Growth hormone
• Slow effects on glucose metabolism.
• major surge during sleep : rise in blood
glucose levels in the early morning: dawn
phenomenon.
• In normal physiology, a slight increase in
insulin secretion compensates
• In diabetes: variable morning hyperglycemia
related to variable nocturnal growth hormone
secretion.
Pathophysiology of diabetes final 2
T1D and advanced T2D: counterregulatory
deficiencies and impaired symptomatic awareness
VISCIOUS CIRCLE

• Hyperglycemia : Glucotoxicity : more
hyper
• Hypogycemia-associated autonomic
failure (HAAF): more hypo
Hypoglycemia Unawareness
•
•
•
•

No early warning symptoms of hypoglycemia
cognitive impairment may be first symptom
Clinical diagnosis
Reduced glucose thresholds for epinephrine-mediated warning
symptoms
• Autonomic dysfunction: inadequate catecholamic release to
hypoglycemia.
Reversible!!
• Avoidance of even mild hypoglycemia for 2–4 weeks.
• Adjustments in glycemic goals
• Education to estimate and detect blood glucose level
fluctuations.
• Increased monitoring of blood glucose
• Modifying glycemic targets until hypoglycemia awareness is
regained.
• Symptom recognition
• AFTER regaining hypoglycemia awareness: reassess the
treatment plan to avoid episodes of hypoglycemia, especially
• nocturnal hypoglycemia.
THANK YOU

More Related Content

PPTX
Insulin types - Insulin Workshop 2021
Usama Ragab
 
PPT
Diabetes Self Management
megbostwick
 
PPT
Hypoglycemia
Ortiz-C
 
PPTX
Recent advances in the management of Diabetes Mellitus
ShailaBanu3
 
PPTX
Diabetes mellitus
jithahari
 
PPTX
Incretins In Diabetes Mellitus
Dr Abhijit Chowdhury
 
PPTX
Diabetes treatment
PranatiChavan
 
PPT
Case studies in the managment of type 2 diabetes
NasserAljuhani
 
Insulin types - Insulin Workshop 2021
Usama Ragab
 
Diabetes Self Management
megbostwick
 
Hypoglycemia
Ortiz-C
 
Recent advances in the management of Diabetes Mellitus
ShailaBanu3
 
Diabetes mellitus
jithahari
 
Incretins In Diabetes Mellitus
Dr Abhijit Chowdhury
 
Diabetes treatment
PranatiChavan
 
Case studies in the managment of type 2 diabetes
NasserAljuhani
 

What's hot (20)

PPTX
Gliclazide MR in the management of Type 2 Diabetes Mellitus
Endocrinology Department, BSMMU
 
PPTX
oral hypoglycemic drugs
Rinky Meena
 
PPTX
Incretin Therapy
ko ko
 
PPTX
Hypoglycemia in dm patients
Mohammad Othman Daoud
 
PPT
Diabetes: screening & diagnosis
Mohsen Eledrisi
 
PPTX
Recent Advances in Obesity Pharmacotherapy
Shreya Gupta
 
PPTX
Degludec insulin journal review
Santosh Narayankar
 
PPTX
Oral hypoglycaemic agents
Haider Haider
 
PPTX
Sulfonylureas for Diabetes: A deep insight
RxVichuZ
 
PPTX
Managing your type ii diabetes: patient education
mdlv1974
 
PPTX
دواءك فى رمضان الكلى
FarragBahbah
 
PPTX
Ryzodeg presentation in ramadan by dr shahjada selim
Bangabandhu Sheikh Mujib Medical University
 
PDF
Treating Obesity: The Way Forward
ecipenm
 
PPTX
Incretins
Medicine Mcq
 
PPTX
Presentation on Hypoglycemia
BANAFULRoy
 
PPTX
Review studies of new insulin products
sara_abudahab
 
PPT
Glimepiride
BALASUBRAMANIAM IYER
 
PPTX
SGLT2I The paradigm change in diabetes management
Praveen Nagula
 
PPT
Resistant hypertension
dranjalivyas
 
Gliclazide MR in the management of Type 2 Diabetes Mellitus
Endocrinology Department, BSMMU
 
oral hypoglycemic drugs
Rinky Meena
 
Incretin Therapy
ko ko
 
Hypoglycemia in dm patients
Mohammad Othman Daoud
 
Diabetes: screening & diagnosis
Mohsen Eledrisi
 
Recent Advances in Obesity Pharmacotherapy
Shreya Gupta
 
Degludec insulin journal review
Santosh Narayankar
 
Oral hypoglycaemic agents
Haider Haider
 
Sulfonylureas for Diabetes: A deep insight
RxVichuZ
 
Managing your type ii diabetes: patient education
mdlv1974
 
دواءك فى رمضان الكلى
FarragBahbah
 
Ryzodeg presentation in ramadan by dr shahjada selim
Bangabandhu Sheikh Mujib Medical University
 
Treating Obesity: The Way Forward
ecipenm
 
Incretins
Medicine Mcq
 
Presentation on Hypoglycemia
BANAFULRoy
 
Review studies of new insulin products
sara_abudahab
 
SGLT2I The paradigm change in diabetes management
Praveen Nagula
 
Resistant hypertension
dranjalivyas
 
Ad

Similar to Pathophysiology of diabetes final 2 (20)

PPTX
Pathophysiology of diabetes by Dr Shahjada Selim
Bangabandhu Sheikh Mujib Medical University
 
PDF
Endocrine pancreas 2025_250211_170431.pdf
t6ffd4hv9n
 
PPT
INSULIN
Dr Nilesh Kate
 
PPTX
1051 carbohydrate metabolism lecture 9 (1)
ssusercc780c
 
PDF
Diabetes Mellitus – Chapter 3 | Pathophysiology, Complications & Management
PKLI-Institute of Nursing and Allied Health Sciences Lahore , Pakistan.
 
PDF
DM Pathogenesis.pdf
DrirFaisalHasan
 
PPTX
الغعاا.pptx
NabdNabd
 
PPTX
ndfhrGlucose metabolism.pptx
NabdNabd
 
PPTX
metablo.pptx
NabdNabd
 
PPTX
regulation of blood sugar
Bala Vidyadhar
 
PPT
Hormones of pancreas (The Guyton and Hall physiology Maryam Fida (o-1827))
Maryam Fida
 
PPTX
Glucose metabolism.pptx
NabdNabd
 
PPTX
الغعااnkgg.pptx
NabdNabd
 
PPTX
blood sugar control-BY VUREMY IRENE.pptx
IreneVuremy
 
PPTX
blood sugar control-BY VUREMY IRENE.pptx
IreneVuremy
 
PPTX
Diabetes and insulin dr jayesh vaghela
jpv2212
 
PPT
Pathophis of carbohydrates and lipids metabolism
Ivano-Frankivsk National Medical University
 
PPTX
Dm pathophysiology bkc
drbalwant choure
 
PPTX
DM.pptx
Shumaila Jameel
 
PPT
The Pancreas
Examville.com LLC
 
Pathophysiology of diabetes by Dr Shahjada Selim
Bangabandhu Sheikh Mujib Medical University
 
Endocrine pancreas 2025_250211_170431.pdf
t6ffd4hv9n
 
1051 carbohydrate metabolism lecture 9 (1)
ssusercc780c
 
Diabetes Mellitus – Chapter 3 | Pathophysiology, Complications & Management
PKLI-Institute of Nursing and Allied Health Sciences Lahore , Pakistan.
 
DM Pathogenesis.pdf
DrirFaisalHasan
 
الغعاا.pptx
NabdNabd
 
ndfhrGlucose metabolism.pptx
NabdNabd
 
metablo.pptx
NabdNabd
 
regulation of blood sugar
Bala Vidyadhar
 
Hormones of pancreas (The Guyton and Hall physiology Maryam Fida (o-1827))
Maryam Fida
 
Glucose metabolism.pptx
NabdNabd
 
الغعااnkgg.pptx
NabdNabd
 
blood sugar control-BY VUREMY IRENE.pptx
IreneVuremy
 
blood sugar control-BY VUREMY IRENE.pptx
IreneVuremy
 
Diabetes and insulin dr jayesh vaghela
jpv2212
 
Pathophis of carbohydrates and lipids metabolism
Ivano-Frankivsk National Medical University
 
Dm pathophysiology bkc
drbalwant choure
 
The Pancreas
Examville.com LLC
 
Ad

More from MEEQAT HOSPITAL (20)

PPT
Updated conscious sedation course.ppt
MEEQAT HOSPITAL
 
PPTX
fatal asthma.pptx
MEEQAT HOSPITAL
 
PPTX
Updated algorithm of ER – ICU - In - patients guidelines.pptx
MEEQAT HOSPITAL
 
PPTX
Blood Bank Lecture .pptx
MEEQAT HOSPITAL
 
PPTX
Post covid -19 syndrome
MEEQAT HOSPITAL
 
PPTX
Sepsis and septic shock guidelines 2021. part 1
MEEQAT HOSPITAL
 
PPTX
Sepsis hemodynamic update part two
MEEQAT HOSPITAL
 
PPTX
sepsis SSC 2021 Updates Ventilation and additional therapy
MEEQAT HOSPITAL
 
PPTX
Sepsis scoring
MEEQAT HOSPITAL
 
PPTX
Surviving sepsis compaign (adults) Guidelines updates 2021. “Long Term Outcom...
MEEQAT HOSPITAL
 
PPTX
Medication error, nursing responsibility
MEEQAT HOSPITAL
 
PPTX
Continuous renal replacement therapy crrt
MEEQAT HOSPITAL
 
PPTX
Deep venous thrombosis dvt
MEEQAT HOSPITAL
 
PPTX
Bed sore management
MEEQAT HOSPITAL
 
PPTX
Chest intubation indications,precautions and management
MEEQAT HOSPITAL
 
PPTX
Portable ventilator
MEEQAT HOSPITAL
 
PPTX
Covid19 corona management -كوفيد19
MEEQAT HOSPITAL
 
PPTX
Sedation
MEEQAT HOSPITAL
 
PPT
Conscious sedation course
MEEQAT HOSPITAL
 
PPTX
Electronic medica file
MEEQAT HOSPITAL
 
Updated conscious sedation course.ppt
MEEQAT HOSPITAL
 
fatal asthma.pptx
MEEQAT HOSPITAL
 
Updated algorithm of ER – ICU - In - patients guidelines.pptx
MEEQAT HOSPITAL
 
Blood Bank Lecture .pptx
MEEQAT HOSPITAL
 
Post covid -19 syndrome
MEEQAT HOSPITAL
 
Sepsis and septic shock guidelines 2021. part 1
MEEQAT HOSPITAL
 
Sepsis hemodynamic update part two
MEEQAT HOSPITAL
 
sepsis SSC 2021 Updates Ventilation and additional therapy
MEEQAT HOSPITAL
 
Sepsis scoring
MEEQAT HOSPITAL
 
Surviving sepsis compaign (adults) Guidelines updates 2021. “Long Term Outcom...
MEEQAT HOSPITAL
 
Medication error, nursing responsibility
MEEQAT HOSPITAL
 
Continuous renal replacement therapy crrt
MEEQAT HOSPITAL
 
Deep venous thrombosis dvt
MEEQAT HOSPITAL
 
Bed sore management
MEEQAT HOSPITAL
 
Chest intubation indications,precautions and management
MEEQAT HOSPITAL
 
Portable ventilator
MEEQAT HOSPITAL
 
Covid19 corona management -كوفيد19
MEEQAT HOSPITAL
 
Sedation
MEEQAT HOSPITAL
 
Conscious sedation course
MEEQAT HOSPITAL
 
Electronic medica file
MEEQAT HOSPITAL
 

Recently uploaded (20)

PPTX
Care of patients with elImination deviation.pptx
AneetaSharma15
 
PPTX
Introduction and Scope of Bichemistry.pptx
shantiyogi
 
PDF
Module 3: Health Systems Tutorial Slides S2 2025
Jonathan Hallett
 
PPTX
NOI Hackathon - Summer Edition - GreenThumber.pptx
MartinaBurlando1
 
PDF
High Ground Student Revision Booklet Preview
jpinnuck
 
PPTX
An introduction to Prepositions for beginners.pptx
drsiddhantnagine
 
PPTX
PREVENTIVE PEDIATRIC. pptx
AneetaSharma15
 
DOCX
Action Plan_ARAL PROGRAM_ STAND ALONE SHS.docx
Levenmartlacuna1
 
PPTX
HISTORY COLLECTION FOR PSYCHIATRIC PATIENTS.pptx
PoojaSen20
 
PPTX
Information Texts_Infographic on Forgetting Curve.pptx
Tata Sevilla
 
PDF
1.Natural-Resources-and-Their-Use.ppt pdf /8th class social science Exploring...
Sandeep Swamy
 
PDF
Sunset Boulevard Student Revision Booklet
jpinnuck
 
PPTX
Skill Development Program For Physiotherapy Students by SRY.pptx
Prof.Dr.Y.SHANTHOSHRAJA MPT Orthopedic., MSc Microbiology
 
PPTX
Odoo 18 Sales_ Managing Quotation Validity
Celine George
 
PDF
PG-BPSDMP 2 TAHUN 2025PG-BPSDMP 2 TAHUN 2025.pdf
AshifaRamadhani
 
PDF
3.The-Rise-of-the-Marathas.pdfppt/pdf/8th class social science Exploring Soci...
Sandeep Swamy
 
PDF
Electricity-Magnetic-and-Heating-Effects 4th Chapter/8th-science-curiosity.pd...
Sandeep Swamy
 
DOCX
SAROCES Action-Plan FOR ARAL PROGRAM IN DEPED
Levenmartlacuna1
 
PPTX
Open Quiz Monsoon Mind Game Prelims.pptx
Sourav Kr Podder
 
PPTX
An introduction to Dialogue writing.pptx
drsiddhantnagine
 
Care of patients with elImination deviation.pptx
AneetaSharma15
 
Introduction and Scope of Bichemistry.pptx
shantiyogi
 
Module 3: Health Systems Tutorial Slides S2 2025
Jonathan Hallett
 
NOI Hackathon - Summer Edition - GreenThumber.pptx
MartinaBurlando1
 
High Ground Student Revision Booklet Preview
jpinnuck
 
An introduction to Prepositions for beginners.pptx
drsiddhantnagine
 
PREVENTIVE PEDIATRIC. pptx
AneetaSharma15
 
Action Plan_ARAL PROGRAM_ STAND ALONE SHS.docx
Levenmartlacuna1
 
HISTORY COLLECTION FOR PSYCHIATRIC PATIENTS.pptx
PoojaSen20
 
Information Texts_Infographic on Forgetting Curve.pptx
Tata Sevilla
 
1.Natural-Resources-and-Their-Use.ppt pdf /8th class social science Exploring...
Sandeep Swamy
 
Sunset Boulevard Student Revision Booklet
jpinnuck
 
Skill Development Program For Physiotherapy Students by SRY.pptx
Prof.Dr.Y.SHANTHOSHRAJA MPT Orthopedic., MSc Microbiology
 
Odoo 18 Sales_ Managing Quotation Validity
Celine George
 
PG-BPSDMP 2 TAHUN 2025PG-BPSDMP 2 TAHUN 2025.pdf
AshifaRamadhani
 
3.The-Rise-of-the-Marathas.pdfppt/pdf/8th class social science Exploring Soci...
Sandeep Swamy
 
Electricity-Magnetic-and-Heating-Effects 4th Chapter/8th-science-curiosity.pd...
Sandeep Swamy
 
SAROCES Action-Plan FOR ARAL PROGRAM IN DEPED
Levenmartlacuna1
 
Open Quiz Monsoon Mind Game Prelims.pptx
Sourav Kr Podder
 
An introduction to Dialogue writing.pptx
drsiddhantnagine
 

Pathophysiology of diabetes final 2

  • 1. Pathophysiology of T2 Diabetes and its Clinical implications. INTESSAR SULTAN 单击此处编辑母版副标题样式 MD, MRCP PROF. OF MEDICINE @ TAIBA UNIVERSITY. CONSULTANT ENDOCRINOLOGIST@ DC, KFH, MADINAH.
  • 2. DEFINITION Diabetes mellitus is metabolic disorder of multiple aetiology characterized by chronic hyperglycaemia with disturbances of carbohydrate, fat and protein metabolism resulting from defects in insulin secretion, insulin action, or both. .
  • 4. NORMAL FUEL METABOLISM Fuel metabolism is regulated by complex system to: • Distribute nutrients to organs and tissues for mechanical or chemical work, growth or renewal • Provide storage of excess nutrients: glycogen or fat • Allow release of energy from storage depots as needed during fasting or high energy use
  • 5. Carbohydrate Metabolism • Glucose is a major energy source for muscles and the brain. • The brain is nearly totally dependent on glucose • Muscles use Glucose And Fat for fuel. • Main sources of circulating glucose are hepatic glucose production, kidney and ingested carbohydrate.
  • 6. Basal Hepatic glucose production: HGP • After absorption of the last meal is complete, liver produce glucose to supply glucose needed for tissues that do not store glucose as brain. • ~2 mg/kg body wt/min in adults.
  • 7. BRIAN • Do not store glucose • Dependent on glucose
  • 8. Mechanisms and sources of glucose release in the post-absorptive state Renal contribution: 2.0–2.5 μmol/(kg−min) (20–25%) Hepatic contribution: 7.5–8.0 μmol/(kg−min) (75–80%) Hepatic glycogenolysis: 4.5–5.5 μmol/(kg−min) (45–50%) Renal gluconeogenesis: 2.0–2.5 μmol/(kg−min) (20–25%) Hepatic gluconeogenesis: 2.5–3.0 μmol/(kg−min) (25–30%) Overall rate of glucose release: ~10 μmol/(kg−min)
  • 9. High HGP In T2DM • Insulin suppresses hepatic glucose production (HGP) • In T2D: impaired hepatic insulin action (Liver resistance): increase BGP: high FBG: diagnosis • High HGP during fasting : hyperglycemia, hyperlipidemia, and ketosis (RAMADAN FASTING). • Metformin: act on liver resistance. Taken at PM , lowers liver production of glucose at night, lowers FBG .
  • 10. Ingested carbohydrate • 60–70% is stored (glycogen) • 30-40% oxidized for immediate energy needs. • Produce postprandial blood glucose 90–120 min after meal. • The magnitude and rate of rise in BG: – size of the meal – physical state (solid, liquid, cooked, raw) – other nutrients: fat and fiber: slow digestion – amount and effect of insulin. – Type simple or complex: least effect – The rate of gastric emptying: delays PP surge with hypoglycemia and rebound hyperglycemia
  • 11. Protein Metabolism Ingested protein is absorbed as amino acids: • synthesis of new protein • oxidation to provide energy • conversion to glucose (gluconeogenesis) during fasting: Alanine • In DM: gluconeogenesis: loss of weight and Fatigue
  • 12. Fat Metabolism • Fat is the major form of stored energy as triglyceride in adipose tissue or muscle fat deposits. • TG is converted to free fatty acids plus glycerol by lipolysis: transported to muscle for oxidation: ketone bodies acetoacetate and –hydroxybutyrate . • Chronic nutritional excess: accumulation of stored fat, because ingested fat is not used and other excess nutrients (glucose) are used to synthesize fat: fatty liver.
  • 13. CLINICAL IMPLICATIONS • Elevated circulating free fatty acids from ingested fat or lipolysis may: • induce hepatic insulin resistance at different sites: LIPOTOXICITY • Increase basal HGP • Slow the postabsorptive decline in blood glucose.
  • 15. Insulin and Glucose Metabolism Major Metabolic Effects of Insulin • Stimulates glucose uptake into muscle and adipose cells: lipogenesis • Inhibits hepatic glucose production Consequences of Insulin Deficiency • Hyperglycemia  osmotic diuresis and dehydration
  • 16. Major Metabolic Effects of Insulin and Consequences of Insulin Deficiency Insulin effects: Stimulates glucose uptake into muscle and adipose cells: lipogenesis + inhibits lipolysis Consequences of insulin deficiency: elevated FFA levels Insulin effects: Inhibits ketogenesis • Consequences of insulin deficiency: ketoacidosis, production of ketone bodies Stimulates glucose uptake into muscle stimulates amino acid uptake and protein synthesis, inhibits protein degradation, regulates gene transcription • Consequences of insulin deficiency: muscle wasting
  • 19. Basal Insulin • Constant low insulin levels • Prevent lipolysis and glucose production. • Low level of basal Insulin during exercise making stored energy available. • Low basal insulin during fasting: increase glucagon : glycogenolysis , lipolysis, and ketogenesis: hyperglycemia, hyperlipidemia, and ketosis.
  • 20. Prandial insulin • Blood glucose is the dominant stimulus for insulin secretion. • Postprandial secretion increases rapidly> basal – Suppress glucose production – Supress lipolysis – stimulate uptake of ingested glucose by tissues
  • 21. The Biphasic prandial Insulin Response Adapted from Howell SL. Chapter 9. In: Pickup JC, Williams G (Eds). Textbook of Diabetes. Oxford. Blackwell Scientific Publications 1991: 72–83.
  • 23. Loss of Early-phase Insulin Release in Type 2 Diabetes Pattern of insulin release is altered early in Type 2 diabetes 120 100 20g glucose 80 60 40 20 0 –30 0 30 60 90 120 Time (minutes) Type 2 diabetes Plasma insulin (µU / ml) Plasma insulin (µU/ml) Normal 120 20g glucose 100 80 60 40 20 0 –30 0 30 60 90 120 Time (minutes) Adapted from Ward WK et al. Diabetes Care 1984; 7: 491–502.
  • 24. Overview of Insulin and Action
  • 26. Glucotoxicity • Hyperglycemia inhibits insulin secretion and impairs insulin action. • Oral agents that increase insulin secretion or improve action could be ineffective at higher levels of hyperglycemia. • Treatment with insulin for a few days to reduce the marked hyperglycemia may make the patient more responsive to subsequent treatment with oral agents.
  • 27. Normal glucose homeostasis Insulin-mediated glucose uptake by skeletal muscle and adipose tissue Glucagon Insulin FPG 90 mg/dL Glucose Glucose filtration/ reabsorption FPG, fasting plasma glucose. Adapted from: DeFronzo RA. Ann Intern Med 1999;131:281–303; Wright EM. Am J Physiol Renal Physiol 2001;280:F10–F18.
  • 28. Pathophysiology in Type 2 DM 1.Decreased insulin and increased glucagon secretion result in... 2.elevated hepatic glucose output... 3. reduced insulin-mediated glucose uptake 4.Hyperglycaemia 5.Renal glucose filtration and reabsorption is increased up to the renal threshold for glucose reabsorption (180 mg/dL): glucosuria 6.Glucotoxicity of all organs, exposing the individual to the risk of complications and further impairing insulin secretion and action
  • 29. Pathophysiology of Type 2 diabetes Insulin-mediated glucose uptake by skeletal muscle and adipose tissue  Glucagon 1  Insulin FPG 90 mg/dL Glucose Glucose filtration/ reabsorption FPG, fasting plasma glucose. Adapted from: DeFronzo RA. Ann Intern Med 1999;131:281–303; Wright EM. Am J Physiol Renal Physiol 2001;280:F10–F18.
  • 30. Pathophysiology of Type 2 diabetes   Insulin resistance is the decreased response of the liver and peripheral tissues (muscle, fat) to insulin Insulin resistance is a primary defect in the majority of patients with Type 2 diabetes
  • 31. Pathophysiology of Type 2 diabetes Insulin-mediated glucose uptake by skeletal muscle and adipose tissue  Glucagon  Insulin 1 FPG 90 mg/dL 2  Glucose Glucose filtration/ reabsorption FPG, fasting plasma glucose. Adapted from: DeFronzo RA. Ann Intern Med 1999;131:281–303; Wright EM. Am J Physiol Renal Physiol 2001;280:F10–F18.
  • 32. Pathophysiology of Type 2 diabetes 3 Insulin-mediated glucose uptake by  skeletal muscle and adipose tissue  Glucagon  Insulin 1 FPG 90 mg/dL 2  Glucose Glucose filtration/ reabsorption FPG, fasting plasma glucose. Adapted from: DeFronzo RA. Ann Intern Med 1999;131:281–303; Wright EM. Am J Physiol Renal Physiol 2001;280:F10–F18.
  • 33. Pathophysiology of Type 2 diabetes 3 Insulin-mediated glucose uptake by  skeletal muscle and adipose tissue  Glucagon  Insulin 1 FPG 90 mg/dL 2  Glucose 4  Glucose filtration/ reabsorption FPG, fasting plasma glucose. Adapted from: DeFronzo RA. Ann Intern Med 1999;131:281–303; Wright EM. Am J Physiol Renal Physiol 2001;280:F10–F18.
  • 34. Pathophysiology of Type 2 diabetes 3 Insulin-mediated glucose uptake by  skeletal muscle and adipose tissue  Glucagon  Insulin 1 FPG 180 mg/dL 2 GLUCOTOXICITY  Glucose 4  Glucose filtration/ reabsorption GLUCOSURIA FPG, fasting plasma glucose. Adapted from: DeFronzo RA. Ann Intern Med 1999;131:281–303; Wright EM. Am J Physiol Renal Physiol 2001;280:F10–F18.
  • 35. Pathophysiology of Type 2 diabetes 3 Insulin-mediated glucose uptake by  skeletal muscle and adipose tissue  Glucagon  Insulin 1 FPG 180 mg/dL 2 GLUCOTOXICITY  Glucose 4  Glucose filtration/ reabsorption GLUCOSURIA FPG, fasting plasma glucose. Adapted from: DeFronzo RA. Ann Intern Med 1999;131:281–303; Wright EM. Am J Physiol Renal Physiol 2001;280:F10–F18.
  • 36. Glucogen synthesis  Glucose oxidation  Glucogen catabolism  Hepatic glucose production Adipocytes uptake TG  Lipid synthesis  (lipoproteinesterase activity ) Lipid mobilization (Hormone sensitive lipase ) ketone (acetone, acetoacetic acid, beta-hydroxybutyric acid)
  • 37. DeFronzo RA. Diabetes. 2009;58:773-795.
  • 38. KIDNEY An adaptive response to conserve glucose.... Glucose ...becomes maladaptive in Type 2 diabetes GLUCOSE SGLT2 plays a crucial role in renal glucose reabsorption In Type 2 diabetes, the kidney’s maximum glucose reabsorption threshold is exceeded, resulting in glycosuria This highlights renal glucose reabsorption as a potential target for treatment of Type 2 diabetes Normal urine GLUCOSURIA SGLT2, sodium-glucose co-transporter-2.
  • 39. Pathophysiologic Approach to Treatment of T2DM Impaired Insulin Secretion  Metformin Thiazolidinediones _ TZDs GLP-1 analogues DPP-4 inhibitors Sulfonylureas Thiazolidinediones Metformin  Hyperglycemia Increased Hepatic Glucose Production Decreased Glucose Uptake DeFronzo RA. Diabetes. 2009;58:773-795.
  • 40. Mechanism of action-SU repaglinide (36 kD) Kir 6.2 nateglinide SUR depolarization SUR ATP glimipiride(65 kD) glyburide(140 kD)
  • 41. Mechanism of action- acarbose Reversible inhibition of oligosaccharide breakdown by -glucosidases Acarbose Acarbose Oligosaccharide Small intestine mucosa
  • 43. SGLTs SGLT1 SGLT2 Site Mostly intestine with some in the kidney Nearly exclusively in the kidney Sugar specificity Glucose or galactose Glucose Affinity for glucose High Km = 0.4 mM Low Km = 2 mM Capacity for glucose transport Low High Role Dietary glucose absorption Renal glucose reabsorption Renal glucose reabsorption SGLT1/2, sodium-glucose co-transporter-1/2. Abdul-Ghani MA, et al. Endocr Pract 2008;14:782–90.
  • 45. Glucagon. • The first line of defense against hypoglycemia in normals • Glucagon rises rapidly when blood glucose levels fall and stimulates HGP. • In type 1 diabetes, glucagon secretion in response to hypoglycemia may be lost.
  • 46. Catecholamines. • Produced at times of stress (“fight or flight”) • Stimulate release of stored energy. • Major defense against hypoglycemia in T1M (POOR glucagon). • IF DEFECTIVE: Hypoglycemia unawareness: severe and prolonged hypoglycemia: • Intensified glucose control only after a period of hypoglycemia avoidance and restoration of catecholamine response.
  • 47. Cortisol. • • • • increases at times of stress. stimulate gluconeogenesis. slower than glucagon not effective in protecting against acute hypoglycemia.
  • 48. Growth hormone • Slow effects on glucose metabolism. • major surge during sleep : rise in blood glucose levels in the early morning: dawn phenomenon. • In normal physiology, a slight increase in insulin secretion compensates • In diabetes: variable morning hyperglycemia related to variable nocturnal growth hormone secretion.
  • 50. T1D and advanced T2D: counterregulatory deficiencies and impaired symptomatic awareness
  • 51. VISCIOUS CIRCLE • Hyperglycemia : Glucotoxicity : more hyper • Hypogycemia-associated autonomic failure (HAAF): more hypo
  • 52. Hypoglycemia Unawareness • • • • No early warning symptoms of hypoglycemia cognitive impairment may be first symptom Clinical diagnosis Reduced glucose thresholds for epinephrine-mediated warning symptoms • Autonomic dysfunction: inadequate catecholamic release to hypoglycemia.
  • 53. Reversible!! • Avoidance of even mild hypoglycemia for 2–4 weeks. • Adjustments in glycemic goals • Education to estimate and detect blood glucose level fluctuations. • Increased monitoring of blood glucose • Modifying glycemic targets until hypoglycemia awareness is regained. • Symptom recognition • AFTER regaining hypoglycemia awareness: reassess the treatment plan to avoid episodes of hypoglycemia, especially • nocturnal hypoglycemia.

Editor's Notes

  • #2: The kidneys and the liver both contribute to the overall quantity of glucose produced by the body (approximately 10 μmol/kg min in total). The human liver and kidneys provide roughly equal amounts of glucose via gluconeogenesis in the post-absorptive state, but the overall production by the liver exceeds that of the kidney due to additional hepatic glycogenolysis.The liver releases the majority of glucose in the post-absorptive state (75–80%) by gluconeogenesis (25–30%)from precursors such as lactate, glycerol, alanineGlycogenolysis makes up the rest of the liver’s glucose production (45–50%, from breakdown of stored glycogen)The kidney, by contrast, contributes 20–25% of the overall glucose productionThe kidney stores very little glycogen and most renal cells lack the necessary enzyme for glucose release from glucagon; hence its glucose production comes entirely from gluconeogenesisReference:Gerich JE. Diabet Med 2010;27:136–42.
  • #26: <Note: Slide title is animated and cannot be viewed properly in slide notes view>Under normal conditions, glucose homeostasis is kept under tight control.The pancreas, skeletal muscle, liver, adipose tissue and kidney are all important in regulating plasma glucose concentrationsInsulin from the pancreas mediates glucose uptake by skeletal muscle and adipose tissue when blood glucose is high, whilst glucagon increases hepatic glucose secretion when blood levels are lowThe kidney mediates glucose filtration and reabsorptionIn Type 2 diabetes, a number of pathophysiological changes take place:Decreased insulin and increased glucagon secretion result in......elevated hepatic glucose output...... and reduced insulin-mediated glucose uptake in the peripheryAs a result, hyperglycaemia occursUnder these circumstances renal glucose filtration and reabsorption is increased up to the renal threshold for glucose reabsorption (about 180 mg/dL), above which glucosuria developsDevelopment of hyperglycaemia causes glucotoxicity, which affects all organs, exposing the individual to the risk of complications and further impairing insulin secretion and actionReferences:DeFronzo RA. Ann Intern Med 1999;113:281–303.Wright EM. Am J Physiol Renal Physiol 2001;280:F10–F18.
  • #27: <Note: Slide title is animated and cannot be viewed properly in slide notes view>Under normal conditions, glucose homeostasis is kept under tight control.The pancreas, skeletal muscle, liver, adipose tissue and kidney are all important in regulating plasma glucose concentrationsInsulin from the pancreas mediates glucose uptake by skeletal muscle and adipose tissue when blood glucose is high, whilst glucagon increases hepatic glucose secretion when blood levels are lowThe kidney mediates glucose filtration and reabsorptionIn Type 2 diabetes, a number of pathophysiological changes take place:Decreased insulin and increased glucagon secretion result in......elevated hepatic glucose output...... and reduced insulin-mediated glucose uptake in the peripheryAs a result, hyperglycaemia occursUnder these circumstances renal glucose filtration and reabsorption is increased up to the renal threshold for glucose reabsorption (about 180 mg/dL), above which glucosuria developsDevelopment of hyperglycaemia causes glucotoxicity, which affects all organs, exposing the individual to the risk of complications and further impairing insulin secretion and actionReferences:DeFronzo RA. Ann Intern Med 1999;113:281–303.Wright EM. Am J Physiol Renal Physiol 2001;280:F10–F18.
  • #32: <Note: Slide title is animated and cannot be viewed properly in slide notes view>Under normal conditions, glucose homeostasis is kept under tight control.The pancreas, skeletal muscle, liver, adipose tissue and kidney are all important in regulating plasma glucose concentrationsInsulin from the pancreas mediates glucose uptake by skeletal muscle and adipose tissue when blood glucose is high, whilst glucagon increases hepatic glucose secretion when blood levels are lowThe kidney mediates glucose filtration and reabsorptionIn Type 2 diabetes, a number of pathophysiological changes take place:Decreased insulin and increased glucagon secretion result in......elevated hepatic glucose output...... and reduced insulin-mediated glucose uptake in the peripheryAs a result, hyperglycaemia occursUnder these circumstances renal glucose filtration and reabsorption is increased up to the renal threshold for glucose reabsorption (about 180 mg/dL), above which glucosuria developsDevelopment of hyperglycaemia causes glucotoxicity, which affects all organs, exposing the individual to the risk of complications and further impairing insulin secretion and actionReferences:DeFronzo RA. Ann Intern Med 1999;113:281–303.Wright EM. Am J Physiol Renal Physiol 2001;280:F10–F18.
  • #33: <Note: Slide title is animated and cannot be viewed properly in slide notes view>Under normal conditions, glucose homeostasis is kept under tight control.The pancreas, skeletal muscle, liver, adipose tissue and kidney are all important in regulating plasma glucose concentrationsInsulin from the pancreas mediates glucose uptake by skeletal muscle and adipose tissue when blood glucose is high, whilst glucagon increases hepatic glucose secretion when blood levels are lowThe kidney mediates glucose filtration and reabsorptionIn Type 2 diabetes, a number of pathophysiological changes take place:Decreased insulin and increased glucagon secretion result in......elevated hepatic glucose output...... and reduced insulin-mediated glucose uptake in the peripheryAs a result, hyperglycaemia occursUnder these circumstances renal glucose filtration and reabsorption is increased up to the renal threshold for glucose reabsorption (about 180 mg/dL), above which glucosuria developsDevelopment of hyperglycaemia causes glucotoxicity, which affects all organs, exposing the individual to the risk of complications and further impairing insulin secretion and actionReferences:DeFronzo RA. Ann Intern Med 1999;113:281–303.Wright EM. Am J Physiol Renal Physiol 2001;280:F10–F18.
  • #34: <Note: Slide title is animated and cannot be viewed properly in slide notes view>Under normal conditions, glucose homeostasis is kept under tight control.The pancreas, skeletal muscle, liver, adipose tissue and kidney are all important in regulating plasma glucose concentrationsInsulin from the pancreas mediates glucose uptake by skeletal muscle and adipose tissue when blood glucose is high, whilst glucagon increases hepatic glucose secretion when blood levels are lowThe kidney mediates glucose filtration and reabsorptionIn Type 2 diabetes, a number of pathophysiological changes take place:Decreased insulin and increased glucagon secretion result in......elevated hepatic glucose output...... and reduced insulin-mediated glucose uptake in the peripheryAs a result, hyperglycaemia occursUnder these circumstances renal glucose filtration and reabsorption is increased up to the renal threshold for glucose reabsorption (about 180 mg/dL), above which glucosuria developsDevelopment of hyperglycaemia causes glucotoxicity, which affects all organs, exposing the individual to the risk of complications and further impairing insulin secretion and actionReferences:DeFronzo RA. Ann Intern Med 1999;113:281–303.Wright EM. Am J Physiol Renal Physiol 2001;280:F10–F18.
  • #35: <Note: Slide title is animated and cannot be viewed properly in slide notes view>Under normal conditions, glucose homeostasis is kept under tight control.The pancreas, skeletal muscle, liver, adipose tissue and kidney are all important in regulating plasma glucose concentrationsInsulin from the pancreas mediates glucose uptake by skeletal muscle and adipose tissue when blood glucose is high, whilst glucagon increases hepatic glucose secretion when blood levels are lowThe kidney mediates glucose filtration and reabsorptionIn Type 2 diabetes, a number of pathophysiological changes take place:Decreased insulin and increased glucagon secretion result in......elevated hepatic glucose output...... and reduced insulin-mediated glucose uptake in the peripheryAs a result, hyperglycaemia occursUnder these circumstances renal glucose filtration and reabsorption is increased up to the renal threshold for glucose reabsorption (about 180 mg/dL), above which glucosuria developsDevelopment of hyperglycaemia causes glucotoxicity, which affects all organs, exposing the individual to the risk of complications and further impairing insulin secretion and actionReferences:DeFronzo RA. Ann Intern Med 1999;113:281–303.Wright EM. Am J Physiol Renal Physiol 2001;280:F10–F18.
  • #36: <Note: Slide title is animated and cannot be viewed properly in slide notes view>Under normal conditions, glucose homeostasis is kept under tight control.The pancreas, skeletal muscle, liver, adipose tissue and kidney are all important in regulating plasma glucose concentrationsInsulin from the pancreas mediates glucose uptake by skeletal muscle and adipose tissue when blood glucose is high, whilst glucagon increases hepatic glucose secretion when blood levels are lowThe kidney mediates glucose filtration and reabsorptionIn Type 2 diabetes, a number of pathophysiological changes take place:Decreased insulin and increased glucagon secretion result in......elevated hepatic glucose output...... and reduced insulin-mediated glucose uptake in the peripheryAs a result, hyperglycaemia occursUnder these circumstances renal glucose filtration and reabsorption is increased up to the renal threshold for glucose reabsorption (about 180 mg/dL), above which glucosuria developsDevelopment of hyperglycaemia causes glucotoxicity, which affects all organs, exposing the individual to the risk of complications and further impairing insulin secretion and actionReferences:DeFronzo RA. Ann Intern Med 1999;113:281–303.Wright EM. Am J Physiol Renal Physiol 2001;280:F10–F18.
  • #37: The adaptive response of the kidney – reabsorption of glucose to provide substrate for energy generation – is largely mediated by SGLT2. Under normal conditions, glucose is filtered and reabsorbed in the kidney, predominantly by SGLT2, and none appears in the urineThis response becomes dysregulated in Type 2 diabetes, when, due to greater expression of SGLT2 (in part a result of hyperglycaemia), glucose filtration and reabsorption is increased. However, excess glucose concentrations also exceed the maximum reabsorption threshold of SGLT2, resulting in glycosuriaIt is therefore possible that renal glucose reabsorption could be targeted to reduce plasma glucose concentrations in patients with Type 2 diabetes
  • #41: At least five different genes encoding SGLTs have been identified in humans, but only two (SGLT1 and 2) have been well characterised.SGLT1 is a high-affinity, low-capacity transporter that is mostly expressed in the intestine, with lesser expression in the kidney. SGLT1 plays a role in absorption of glucose from both the diet and the glomerular filtrateSGLT2 is a low-affinity, high-capacity transporter that is exclusively expressed in the kidney. It is responsible for the majority (~90%) of glucose reabsorption from the glomerular filtrateReference:Abdul-Ghani MA, et al. EndocrPract2008;14:782–90.